KA
NKTR icon

Kaizen Advisory’s Nektar Therapeutics NKTR Stock Holding History

Kaizen Advisory’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$489K Sell
990
-186
-16% -$112K 0.34% 121
2018
Q3 		$1.07M Buy
1,176
+1,144
+3,575% +$976K 0.56% 37
2018
Q2 		$24K Buy
+32
New +$36.9K 0.01% 492

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kaizen Advisory's NKTR Position: Q4 2018 in Review

Kaizen Advisory reduced its Nektar Therapeutics (NKTR) stake by 16% in Q4 2018, selling an estimated $112K and leaving 990 shares worth $489K. The position accounts for 0.34% of the portfolio, ranked #121.

Kaizen Advisory first reported a position in NKTR in Q2 2018 and has held it in 3 quarters since. The position peaked at $1.07M in Q3 2018. 342 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Kaizen Advisory held 990 shares of Nektar Therapeutics worth $489K as of Q4 2018.
  • Kaizen Advisory sold 186 Nektar Therapeutics shares in Q4 2018, an estimated $112K.
  • Nektar Therapeutics made up 0.34% of Kaizen Advisory's portfolio in Q4 2018, its #121 holding.
  • Kaizen Advisory first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 3 quarters since.
  • Kaizen Advisory's Nektar Therapeutics position peaked at $1.07M in Q3 2018.
  • 342 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Kaizen Advisory's 13F filing for Q4 2018, filed 15 Feb 2019.